NeuroSense Plans Canadian PrimeC ALS Filing for March 2027
NeuroSense plans to file a Canadian application for its ALS drug PrimeC in March 2027, with new biomarker data.
NeuroSense plans to file a Canadian application for its ALS drug PrimeC in March 2027, with new biomarker data.